WR Grace and Formac Pharmaceuticals have announced positive data from initial human studies demonstrating the use of mesoporous silica for drug delivery.
The study has demonstrated the bioavailability enhancing properties of silica in humans, which enables active pharmaceutical ingredients to effectively absorb into the body.
Grace New Business Development vice president George Young said, "The successful completion of this study marks an important milestone for our strategic partnership with Formac as we embark on the development and commercialization of this novel approach for improved drug delivery."
In the study, the bioavailability profile of fenofibrate formulated with silica was compared to the marketed micronized formulation (Lipanthyl), which showed a 54% higher bioavailability for the silica formulation than the marketed formulation.